Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 145 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 Telehealth Can Save People with Cancer Time, Travel, and Money February 16, 2023 FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... April 20, 2021 Load more HOT NEWS Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... Cancer in My Community: Bringing Palliative Care to People With Cancer... Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with... FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2...
